Article
Comparative Liquid Biopsy Testing for KRAS Mutations From Plasma Cell-Free DNA (cfDNA) and Extracellular Vesicles in Lung Adenocarcinoma.
Cancer reports (Hoboken, N.J.) - 1 Mar 2026
Zahra Caeli J, Chee Tian Mun, Stephens Edward K H, Keir Elizabeth J, Parris Brielle A, O'Farrell Hannah E, Goldsworthy Anita F, Bowman Rayleen V, Yang Ian A, Fong Kwun M
Abstract excerpt
BACKGROUND: Liquid biopsy has emerged as a promising, minimally invasive tool to detect cancer biomarkers. Extracellular vesicles (EVs) are secreted into biofluids to transport cargo such as DNA and are a potential biosource for liquid biopsy biomarkers. To determine the optimal use of liquid biopsy for diagnosing mutations in lung adenocarcinoma (LUAD), we compared the KRAS mutation status in DNA isolated from...
Topics
Join the communities discussing this publication.